Media headlines about Oncobiologics (NASDAQ:ONS) have trended somewhat positive on Tuesday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Oncobiologics earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news stories about the company an impact score of 42.4211995556201 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Oncobiologics (ONS) traded down $0.03 during mid-day trading on Tuesday, hitting $1.16. The stock had a trading volume of 53,000 shares, compared to its average volume of 45,778. Oncobiologics has a 1-year low of $0.78 and a 1-year high of $3.95. The company has a debt-to-equity ratio of -0.40, a current ratio of 0.14 and a quick ratio of 0.14.
In other Oncobiologics news, CFO Lawrence A. Kenyon sold 26,165 shares of the stock in a transaction on Friday, December 22nd. The stock was sold at an average price of $1.13, for a total value of $29,566.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Pankaj Mohan sold 104,131 shares of the stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $1.15, for a total value of $119,750.65. The disclosure for this sale can be found here. Insiders sold 284,508 shares of company stock valued at $328,317 in the last quarter. 33.50% of the stock is currently owned by company insiders.
Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.